Paediatric European Group A Streptococcal United Study.

Summary

Introduction Since 2022 there are reports of a rapid increase in invasive group A streptococcal infections (iGAS) in children in some but not all European countries. Detailed information on this increase is lacking. Furthermore, an increase in other invasive infections as well as the emergence of novel pathogens and disease entities is seen, such as MIS-C and severe hepatitis of unknown origin.

Aims To set up a European research network and describe the incidence, risk factors, clinical phenotypes, microbiology and resistance, treatment, and outcomes of iGAS in children across Europe. The network will subsequently be utilized for early alerting regarding the rise of other invasive and emerging infections in children. It will enable swift data collection pertaining to patient characteristics, presentation, progression, and treatment.

Methods International, retrospective cohort and observational surveillance study of children 0-18y attending the ED or admitted to the hospital with iGAS. Clinical and microbiological data, national vaccination schedules, and COVID non-pharmaceutical interventions (NPIs) will be collected and compared between countries. Subsequently, the network will be employed to raise alarms regarding the surge of other invasive infections or emerging infections in children. Anonymous data about these novel infections will be collected, similar to the data from iGAS (clinical characteristics and microbiological data). The study is a non-profit study.

Significance Our study will describe variation in the clinical phenotypes of iGAS, will aid in the understanding of its association with COVID NPIs and allow for comparison between countries. Furthermore, it will aid in early recognition of invasive and emergent infectious diseases in children and the reduction of outbreaks.

Conditions

• Invasive Group A Beta-Haemolytic Streptococcal Disease

Interventions

OTHER

No intervention

no intervention, this is an observational study

Sponsors & Collaborators

• European Society for Paediatric Infectious Diseases

  collaborator OTHER

• Medical University of Graz

  collaborator OTHER

• University Hospital Munich

  collaborator OTHER

• National and Kapodistrian University of Athens

  collaborator OTHER

• Mitera Hospital

  collaborator OTHER

• Children's hospital Iceland

  collaborator UNKNOWN

• University of Padova

  collaborator OTHER

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS

  collaborator OTHER

• Riga Stradins University

  collaborator OTHER

• Maasstad Hospital

  collaborator OTHER

• HagaZiekenhuis

  collaborator OTHER

• Leiden University Medical Center

  collaborator OTHER

• Wroclaw Medical University

  collaborator OTHER

• University Medical Centre Ljubljana

  collaborator OTHER

• Hospital Clínico Universitario de Santiago de Compostela

  collaborator UNKNOWN

• Hospital Universitario 12 de Octubre

  collaborator OTHER

• Hospital Universitario La Paz

  collaborator OTHER

• Gregorio Marañón Hospital

  collaborator OTHER

• Karolinska Institutet

  collaborator OTHER

• Imperial College London

  collaborator OTHER

• University of Liverpool

  collaborator OTHER

• Newcastle University

  collaborator OTHER

• Noordwest Ziekenhuisgroep

  lead OTHER

Eligibility

Min Age

0 Years

Max Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-09-20

Primary Completion

2025-12-01

Completion

2025-12-01

Countries

• Netherlands

Study Locations